The UMP Healthcare Holdings Limited 2025/2026 Interim Report covers the six months ended 31 December 2025, presenting financial and operational highlights amid a challenging macroeconomic environment in Hong Kong.

Financial Performance:

• Total revenue slightly edged down by 1.0% to HK$367.53  million, reflecting softer outpatient demand due to cautious spending and cross competition.
• Net income rose 2.5% YoY to HK$18.39 million (up from HK$ 17.95 million), with basic EPS HK$ 0.0236 (vs HK$ 0.0225)

Business Segment Review:

• Corporate Healthcare Solutions: Revenue HK$ 135.8 million, up by 2.0%, driven by group/individual plans and insurer partnerships; resilient voucher utilization.
• Hong Kong and Macau Clinical Healthcare Services faced revenue decline 0.3%, Outpatient pressured by the competition and sentiment;
• Mainland China Clinical Healthcare Services HK$ 20 million range; stable contribution.

UMP emphasized operational excellence, digital transformation, and financial discipline to sustain growth. Investments in digital platforms, including a new patient management system and AI-assisted diagnostics, aimed to improve efficiency and patient experience. The company also strengthened public-private partnerships and leveraged cross-boundary healthcare opportunities within the Greater Bay Area.

Financial Position:

• Cash, bank balances and deposits increased to HK$338.1 million, ensuring strong liquidity, with no bank borrowings.

.

In summary, despite external economic challenges and sector-specific pressures, UMP Healthcare Holdings Limited demonstrated resilient financial and operational performance in the first half of FY25/26, achieving higher profitability through efficiency improvements and strategic initiatives, while positioning itself well for future growth in integrated healthcare delivery across Hong Kong, Macau, and Mainland China.

「註：本人倪國權為證監會持牌人士。截至本評論文章發表日止，本人及/或其有聯繫者並無持有全部提及之証券的所有相關財務權益。」; Or
” I, Ni Kwok Kuen Alex, am a licensed person under the Securities and Futures Commission. Until the date this commentary was published, neither I and/or my affiliates are the beneficiary of the securities mentioned herein or are entitled to any financial interests in relation thereto. “